Table 1.
EDSS scores arranged by MS clinical pattern and MS therapy type
| L-DS MS group |
H-DS MS group |
All MS participants |
||||
|---|---|---|---|---|---|---|
| n | % | n | % | n | % | |
| MS type | 55 | 25 | 80 | |||
| RRMS | 55 | 100 | 8 | 32 | 63 | 78.75 |
| PRMS | – | – | 9 | 36 | 9 | 11.25 |
| PPMS | – | – | 1 | 4 | 1 | 1.25 |
| SPMS | – | – | 7 | 28 | 7 | 8.75 |
| Received MS therapy | ||||||
| IFN-β 1a | 26 | 47.3 | 3 | 12 | 29 | 36.25 |
| IFN-β 1b | 10 | 18.2 | 5 | 20 | 15 | 18.75 |
| Glatiramer acetate | 6 | 10.9 | 3 | 12 | 9 | 11.25 |
| Fingolimod | 2 | 3.6 | 2 | 8 | 4 | 5 |
| Natalizumab | 1 | 1.8 | 3 | 12 | 4 | 5 |
| Immunosuppressant | 1 | 1.8 | 3 | 12 | 4 | 5 |
| Symptomatic medical treatment | 3 | 5.5 | 4 | 16 | 7 | 8.75 |
| Followed without medical treatment | 6 | 10.9 | 2 | 8 | 8 | 10 |
| MS disability distribution ratio | 68.75 | 31.25 | ||||
PRMS = Progressive-relapsing MS; PPMS = primary-progressive MS; SPMS = secondary-progressive MS.